Predictive Oncology Faces Challenges Compared to Peers

Got story updates? Submit your updates here. ›

Predictive Oncology (NASDAQ:AGPU), a medical technology company focused on developing personalized cancer therapies, faces significant challenges compared to its industry peers. The company has a higher stock price volatility, lower institutional and insider ownership, and weaker profitability metrics than the average 'Surgical, Medical, And Dental Instruments And Supplies' company.

Why it matters

As a publicly-traded company, Predictive Oncology's performance and competitive positioning are important factors for investors and the broader medical technology industry. The company's struggles highlight the competitive pressures and operational hurdles it must overcome to succeed against more established players.

The details

Predictive Oncology has a beta of 1.41, meaning its stock price is 41% more volatile than the S&P 500, while its competitors average a beta of 1.76. Additionally, only 9% of Predictive Oncology's shares are owned by institutional investors, compared to 22.5% for the industry. The company also has lower insider ownership at 1.2% versus 18.4% for its peers. In terms of profitability, Predictive Oncology's competitors have higher revenue and lower earnings per share, but better net margins, return on equity, and return on assets.

• The analysis was published on February 18, 2026.